A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance.
We treated a patient who was hyperthyroid due to Graves' disease and strongly resistant to methimazole (MMI): in spite of good compliance, she needed 150 mg of MMI daily to control her hyperthyroidism. To elucidate the reasons of resistance to MMI, her serum and intrathyroidal MMI concentrations were determined by high pressure liquid chromatography (HPLC). After taking a 30 mg dose of MMI, she had a similar serum MMI concentration-time curve to that of a normal subject: drug malabsorption and rapid drug metabolism were not evident when studied after surgical treatment. After her serum containing MMI was incubated with Protein G, the MMI concentration of the fraction not bound to Protein G did not change significantly from that of untreated serum: the possibility of anti-MMI IgG antibody production was considered unlikely. Furthermore, the intrathyroidal concentration of MMI in a surgically obtained tissue specimen was 3 micrograms/g wet tissue and appeared to be comparable with those of other Graves' tissues reported. Considering that the patient had been taking 150 mg per day of MMI by the time of thyroidectomy, her intrathyroidal MMI concentration was relatively low, suggesting possible impairment of intrathyroidal MMI accumulation. The possibilities of impaired intrathyroidal actions and the severity of hyperthyroidism, especially high T3 levels, also remained as possible causes. In conclusion, here was a severely hyperthyroid patient who was poorly responsive to conventional doses of MMI, and impairment of thyroid uptake of MMI or of pathways after uptake were considered as possible mechanisms.
Li
H
H
Department of Laboratory Medicine, Kyoto University, Japan.
Okuda
J
J
Akamizu
T
T
Mori
T
T
D000328:Adult; D013956:Antithyroid Agents / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004351:Drug Resistance; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008713:Methimazole / Q000493:pharmacokinetics*; D013963:Thyroid Hormones / Q000097:blood*; D014018:Tissue Distribution
D013956:Antithyroid Agents; D013963:Thyroid Hormones; D008713:Methimazole